Xultophy® is a new combination product consisting of basal insulin (degludec) and a GLP-1 agonist (liraglutide). In this article, we analyzed recent literature in order to find out its potential advantages in general and compared to basal insulin in particular, as well as to clarify its role in the therapeutic management of insulinrequiring type 2 diabetes.
Key words
Xultophy®, degludec/liraglutide, type 2 diabetes, HbA1c, weight, hypoglycemia, indications